Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

NCT00324987 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

12

Enrollment

NIH

Sponsor class

Stopped The trial failed to accrue

Conditions

Gastrointestinal Stromal Tumor

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Imatinib Mesylate
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)